Virbac Offers New BRD Vaccine With Three Extra Layers of Protection

WESTLAKE, Texas [November 9, 2026] —Reaffirming its commitment to advancing preventive cattle health, Virbac is expanding its BOVIGEN^® Platinum Vaccine line with BOVIGEN^® Platinum Synvera, an 8-way BRD vaccine developed to bring herds a broader layer of respiratory defense.

Bovine Respiratory Disease (BRD) remains one of the most persistent and costly health challenges facing cattle producers and veterinarians today, directly impacting calf well-being and long-term herd performance.

BOVIGEN^® Platinum Synvera protects against the most prevalent strains of bovine viral diarrhea virus (BVD),^1,2 because it includes BVD types 1 and 2. Vaccine strain BVD 1a has demonstrated cross-protection against 1b. BOVIGEN^® Platinum Synvera effectively protects against infectious bovine rhinotracheitis virus (IBR), bovine parainfluenza 3 virus (PI3) and bovine respiratory syncytial virus (BRSV), Mannheimia haemolytica genotypes 1 and 2 and Pasteurella multocida killed whole bacterins.

BOVIGEN^® Platinum Synvera’s three additions to the traditional 5-way BRD vaccine provide coverage against the entire disease-causing intruder, not just its weapon of choice — the leukotoxin. By combining the 2 key genotypes of Mannheimia haemolytica and one of Pasteurella multocida, this vaccine ensures a broad protection against these bacteria.

“With BOVIGEN^® Platinum Synvera Vaccine, the calf develops antibodies against these bacteria and viruses, providing comprehensive protection all along the airways and lungs,” says Fabrice Payot, Virbac vice president of new business. “Modified-live vaccines stimulate a strong, long-lasting immune response, providing robust disease protection.”

Because gram-negative Mannheimia bacteria are known to cause strong reactions, these vaccines are produced to reduce endotoxins [lipopolysaccharides (LPS)] for a less stressful experience on calves.

“Many of the vaccines on the market are effective in BRD protection, but some can be hard on calves. We wanted to explore a better way and create a solution our team would feel confident putting into our own cattle, focusing on pragmatic vaccinal strains that check every box for efficacy and safety. ” says Payot.

Preliminary field safety studies, in a calf-crop sample size (247), showed that none of the vaccinated calves went off feed or showed negative effects of vaccination. No animals showed adverse reactions, and only 31 showed normal injection site swellings that reduced within 21 days. Calves were tested in three distinct geographical locations around the United States.³

To support cattle producers with complete peace of mind, BOVIGEN^® Platinum Synvera is backed by the BOVIGEN^® Platinum Protection Program. Virbac offers a satisfaction guarantee with a full refund within 6 months of purchase if you are not satisfied with the vaccine’s performance.

Learn more about Virbac’s BOVIGEN^® Platinum Synvera Vaccine at https://us.virbac.com/products/cattle-vaccines/bovigenr-platinum-synvera-vaccine.

Virbac is an independent pharmaceutical company exclusively dedicated to animal health since 1968. At Virbac, we are constantly exploring new ways to prevent, diagnose and treat the majority of animal diseases. We develop care, hygiene and nutrition products to offer complete solutions to veterinarians, farmers and pet owners around the world. Our purpose: advancing the health of animals with those who care for them every day, so we can all live better together.

References:
1. Fulton RW, Cook BJ, Payton ME, et al. Immune response to bovine viral diarrhea virus (BVDV) vaccines detecting antibodies due to BVDV subtypes 1a, 1b, 2a and 2c. Vaccine 2020;38(24):4032–4037.
2. Fulton, RW, Ridpath, JF, Saliki, JT, Briggs, RE, Confer, AW, Burge, LJ, Purdy, CW, Loan, RW, Duff, GC, Payton, ME, Bovine viral diarrhea virus (BVDV) 1b: predominant BVDV subtype in calves with respiratory disease. The Canadian Journal of Veterinary Research 2002;66:181-190.
3. Data on file. Diamond Animal Health.